RE:RE:Once LABS is associated with the name of their global pharma52 week high is .10c..considering multiple imminent events....10m Hexo settlement(1/3rd) of current market cap, ...SEDDS capsule launch for clinical and adult use markets domestically and globally("second half 2023"),...ED mentioned ANVISA approval for NEW top 3, Brazilian generic pharma customer..Australian OTC approval..very long overdue..anyday IMO...cross integration of MPL and VIVO products such as VIVO flower into GERMANY, MPL oils into harvest channels and MYMEDI.CA(expanded partnership with VIVO)...imminent U.S rescheduling...Canadian Government indipendent review conclusion (Jan 2024)...excise tax slashed from 1per gram... IMO..and countless pharma opportunities...which my research into process is much closer than years...I just don't see how this SP can stay this low much longer.. multiples higher by year end ..30-40c IMO..